Superbugs & You CIDRAP

 
Over the past decade, several strains (types) of Salmonella typhi have become resistant to multiple antibiotics. Resistant strains have been identified across the globe. However, the 2018 launch of a vaccine has slowed infections. It is estimated that TCV introduction with a catch-up campaign will avert 42.5 million cases and 506,000 deaths caused by fluoroquinolone-resistant typhoid fever, and 21.2 million cases and 342,000 deaths from multidrug-resistant typhoid fever over 10 years following introduction. This episode will cover the impact of vaccinations and the challenges to deploy effective programs. 
 
Guests:
Farah Naz Qamar -Pediatric Infectious Disease Associate Professor, The Aga Khan University, PakistanKathy Neuzil - Director of the Center for Vaccine Development and Global Health, University of Maryland School of MedicineDenise Garrett - Vice President, Applied Epidemiology, Sabin Vaccine InstituteCalman MacLennan - Senior Program Officer, Bacterial Vaccines, Bill and Melinda Gates Foundation 
For more information on the impact of typhoid conjugate vaccines and AMR, check out CIDRAP-ASP's report, A Vaccine Is a Bridge: The New Era of Typhoid Prevention.

 
Episode Eleven: Fighting for the Future: Neonatal Sepsis
Despite great improvements in mortality for children under 5, sepsis remains a leading cause of death in young children. The highest incidence and mortality were seen in newborns, with the biggest impact seen in low- and middle-income countries in sub-Saharan Africa and Asia. This episode will highlight how the availability of guidelines, diagnostics, and therapeutics can make a difference in the smallest of patients. Content warning: this episode contains discussions of infant loss.
Guests:
Kamala Thiagarajan - Freelance journalist, Global health and environmental sciencesSeamus O’Brien - Director of Research and Development, Global Antibiotic Research and Development ProgramPhoebe Williams - Pediatrician, Infectious Disease Physician, Faculty of Medicine,  University of SydneyMaterials Mentioned in this Episode
Neonatal sepsis: the new threat posed by superbugs, Kamala Thiagarajan, BBCAntibiotics needed to treat multidrug-resistant infections in neonates, Phoebe Williams, …, Seamus O’Brien et al., Bulletin of the World Health Organization

Around the world, the multidrug resistant and pan-resistantfungus Candida auris has caused outbreaks in healthcare systems. While it is now highlighted by CDC as an urgent threat, only six years ago there were no reports of resistant C. auris strains that were able to spread easily between patients. These infections are challenging to treat a with 5% — 10% of colonized patients going on to develop invasive infections. This episode will cover how these outbreaks have impacted patients, healthcare systems, and continued efforts to better understand and slow the impact of these infections.
Guests:
Tom M Chiller - Chief, Mycotic Diseases Branch, Centers for Disease Control and PreventionAndrew Jacobs - Reporter, Health and Science desk, The New York TimesBhavarth Shukla - Associate Professor, Division of Infectious Diseases, University of MiamiMaterials Mentioned in this Episode
A Mysterious Infection, Spanning the Globe in a Climate of Secrecy, Matt Richtel and Andrew Jacobs, The New York Times2022 Special Report: COVID-19 U.S. Impact on Antimicrobial Resistance, Centers for Disease Control and Prevention

Defined as ​an “urgent” AMR threat by the US CDC, resistant Acinetobacter baumanii cause deadly infections and are difficult to remove from the environment. Acinetobacter is resistant to many antibiotics and is a frequent cause of hospital acquired infections. In the 2022 Lancet publication on drug-resistant infections (GRAM report), it was identified as the leading pathogen causing mortality in Southeast Asia. This episode will cover how infections caused by resistant Acinetobacter impact patients and on how new treatments are making an impact.
Guests:Steffanie Strathdee - Associate Dean of Global Health Sciences, University of California San Diego School of Medicine; Author, The Perfect PredatorGreg Merril - CEO, Adaptive Phage TherapeuticsPatrick McGann - Deputy Director, Multidrug-Resistant Organism Repository and Surveillance Network (MRSN)Jason Bennett - Director, MRSN; Associate Professor of Medicine, Walter Reed Army Institute of Research

Join us for a sneak peak of Season 3 of Superbugs and You by listening to a portion of our interview with Dr. Tom Chiller, Chief of the Mycotic Diseases Branch at the Centers for Disease Control and Prevention, discussing Candida auris.

Neisseria gonorrhoeae is the second most common bacterial sexually transmitted infection in the world, and it has become a superbug. It has developed resistance to every antibiotic currently approved for treatment, and multidrug-resistant strains have been identified globally. Hear from clinicians advocating for their patients, a global leader, and a leading expert in drug development on actions needed to combat resistant gonorrhea.